On track to initiate Phase 3 trials within the EMERGENT program, the clinical program evaluating KarXT for the treatment of acute psychosis in patients with schizophrenia, by the end of 2020 Topline data from Phase 1b trial in healthy elderly volunteers expected by the end of 2020 Plans to

Topline results of exploratory trial do not provide conclusive evidence of an analgesic benefit of KarXT on experimentally induced pain in healthy volunteers The Company will not move forward to evaluate KarXT for the treatment of pain The safety and tolerability profile of KarXT was consistent

BOSTON --(BUSINESS WIRE)--Jul. 30, 2020-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and

Multi-year drug discovery collaboration leveraging behavioral and physiological phenotypic screening and machine learning to identify novel neuropsychiatric drug candidates BOSTON & PARAMUS, N.J. --(BUSINESS WIRE)--Jul. 28, 2020-- Karuna Therapeutics, Inc.

One additional Phase 3 trial, along with previously completed Phase 2 trial, would be acceptable to support an efficacy claim for a New Drug Application filing Company on track to initiate Phase 3 program, including efficacy and open-label long-term safety trials, by the end of 2020 BOSTON

BOSTON --(BUSINESS WIRE)--Jun. 3, 2020-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and

BOSTON --(BUSINESS WIRE)--May 27, 2020-- Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain,

End of Phase 2 meeting scheduled with the U.S. Food and Drug Administration (FDA) with feedback from the meeting expected to be announced in the second quarter Additional data from Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia to be presented at

BOSTON --(BUSINESS WIRE)--Apr. 28, 2020-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today

BOSTON --(BUSINESS WIRE)--Mar. 26, 2020-- Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today